Abstract
Understanding the mechanisms underlying different cellular signaling pathways implicated in the pathogenesis of cancer are leading to the identification of novel drug targets as well as novel drug candidates. Multiple targeted therapeutics that modulate aberrant molecular pathways have already reached the clinic. However, targeted therapeutics can exert mechanism-driven side effects as a result of the implication of the molecular target in normal physiological functions besides tumorigenesis. We hypothesize that targeted therapeutics can be optimized by merging them with nanotechnology, which offers the potential for preferential targeting to the tumor, resulting in increased intratumoral concentrations of the active agent with reduced distribution to other parts of the body. This review will address some of the emerging concepts that integrate these two disciplines to engineer novel nanovectors that target different signaling pathways.
Keywords: Nanotechnology, drug delivery, signaling pathways, nanoparticles, cancer, RECEPTOR KINASES, Downstream Signaling, ONCOGENIC SIGNALING, EGFR-overexpressing cancer
Current Drug Delivery
Title: Cancer, Signal Transduction and Nanotechnology
Volume: 8 Issue: 3
Author(s): Poulomi Sengupta, Sudipta Basu and Shiladitya Sengupta
Affiliation:
Keywords: Nanotechnology, drug delivery, signaling pathways, nanoparticles, cancer, RECEPTOR KINASES, Downstream Signaling, ONCOGENIC SIGNALING, EGFR-overexpressing cancer
Abstract: Understanding the mechanisms underlying different cellular signaling pathways implicated in the pathogenesis of cancer are leading to the identification of novel drug targets as well as novel drug candidates. Multiple targeted therapeutics that modulate aberrant molecular pathways have already reached the clinic. However, targeted therapeutics can exert mechanism-driven side effects as a result of the implication of the molecular target in normal physiological functions besides tumorigenesis. We hypothesize that targeted therapeutics can be optimized by merging them with nanotechnology, which offers the potential for preferential targeting to the tumor, resulting in increased intratumoral concentrations of the active agent with reduced distribution to other parts of the body. This review will address some of the emerging concepts that integrate these two disciplines to engineer novel nanovectors that target different signaling pathways.
Export Options
About this article
Cite this article as:
Sengupta Poulomi, Basu Sudipta and Sengupta Shiladitya, Cancer, Signal Transduction and Nanotechnology, Current Drug Delivery 2011; 8 (3) . https://dx.doi.org/10.2174/156720111795256147
DOI https://dx.doi.org/10.2174/156720111795256147 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advances of natural products, bio-actives and novel drug delivery system against emerging viral infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access of both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Nanotechnology Based Chemotherapy for the treatment of Head & Neck Cancer
The escalating recurrence rates observed in Head and Neck cancer, particularly within the chemo-therapeutically treated cohort (50-60%), can be attributed to the non-selective nature of current anticancer drug delivery modalities. In this context, nanotechnology-based drug delivery systems emerge as a promising avenue for achieving precise localization of therapeutic agents to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pharmacometrics of Stilbenes: Seguing Towards the Clinic
Current Clinical Pharmacology Clinical Evaluation of Natural History of Peyronie’s Disease: Our Experience, Old Myths and New Certainties
Inflammation & Allergy - Drug Targets (Discontinued) Gene Expression-Based Pharmacodynamic Biomarkers: The Beginning of a New Era in Biomarker-Driven Anti-Tumor Drug Development
Current Molecular Medicine Expression of Specificity Protein Transcription Factors in Pancreatic Cancer and their Association in Prognosis and Therapy
Current Medicinal Chemistry Withdrawal Notice: TP53 Targetome: A Database of Novel Breast Cancer Biomarkers
Current Drug Targets Micro-RNA in Disease and Gene Therapy
Current Drug Discovery Technologies Metabolomics-based Approach to Pharmacotherapy Personalization: Advantages and Limitations
Current Pharmacogenomics and Personalized Medicine Formulation and Optimization of 5-Fluorouracil Loaded Chitosan Nanoparticles Employing Central Composite Design
Drug Delivery Letters OX40:OX40L Axis: Emerging Targets for Immunotherapy of Human Disease
Current Immunology Reviews (Discontinued) Synthetic Small Molecule Inhibitors of Hh Signaling As Anti-Cancer Chemotherapeutics
Current Medicinal Chemistry Targeting Mevalonate Pathway in Cancer Treatment: Repurposing of Statins
Recent Patents on Anti-Cancer Drug Discovery 1,3,4-Thiadiazolo (3,2-Α) Pyrimidine-6-Carbonitrile Scaffold as PARP1 Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Bioactive N-Phenylimidazole Derivatives
Current Chemical Biology Defining and Managing Expectations for Early Immunotherapy Cancer Trials
Reviews on Recent Clinical Trials The Supremacy of Synergism: A Comparison of Anticancer Activity of Rhizome Extract of Bistorta Amplexicaulis and Gallic Acid in Cancer Cell Lines and Primary Cells
Current Nutraceuticals Investigation of <i>ACE rs4646994, MTHFR rs1801133</i> and <i>VDR rs2228570</i> Genotypes in Jordanian Patients with Fibromyalgia Syndrome
Endocrine, Metabolic & Immune Disorders - Drug Targets The ERK and p38MAPK Pathways as Targets for Anti-Inflammatory Therapy
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Tannic Acid Inhibits Proliferation, Migration, Invasion of Prostate Cancer and Modulates Drug Metabolizing and Antioxidant Enzymes
Anti-Cancer Agents in Medicinal Chemistry Progress Towards Clinically Useful Aldosterone Synthase Inhibitors
Current Topics in Medicinal Chemistry Prevention of Ischemic Stroke: Antithrombotic Therapy in Cardiac Embolism
Current Drug Targets